Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 4/20 | 0.45 |
| ▸ | CCR8 | P51685 | 1/20 | 0.39 |
| ▸ | SSTR5 | P35346 | 4/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14169117 | 0.90 | CCR8 (0.49) | CCR8MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL1495215 | 0.88 | SSTR5 (0.39) | NPY1RSSTR5MEN1KMT2AKCNH2 | |
| SCHEMBL8287184 | 0.87 | SSTR5 (0.43) | NPY1RSSTR5MEN1KMT2AKCNH2 | |
| SCHEMBL1495258 | 0.87 | SSTR5 (0.40) | NPY1RSSTR5MEN1KMT2AKCNH2 | |
| SCHEMBL8287182 | 0.83 | NR4A2 (0.46) | NPY1RSSTR5KCNH2NR4A2 | |
| SCHEMBL8288281 | 0.82 | SSTR5 (0.38) | NPY1RSSTR5MEN1KMT2AKCNH2 | |
| SCHEMBL1495344 | 0.79 | NPY1R (0.44) | NPY1RSSTR5MEN1KMT2AKCNH2 | |
| SCHEMBL1495206 | 0.77 | SSTR5 (0.41) | NPY1RSSTR5MEN1KMT2AKCNH2 | |
| SCHEMBL8294770 | 0.76 | PDE5A (0.37) | NPY1RSSTR5KCNH2NR4A2KDM4E | |
| SCHEMBL14169009 | 0.76 | NOS2 (0.46) | MEN1KMT2AKDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1723136-B1 | PIPERIDINE-AMINO-BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | TIBOTEC PHARM LTD (IE) | 2011-03-09 | — | — | EP | disclosed |
| US-20080146613-A1 | PIPERIDINE-AMINO-BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-06-19 | — | — | US | disclosed |
| US-20080146613-A1 | PIPERIDINE-AMINO-BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-06-19 | — | — | US | disclosed |
| US-7355051-B2 | Piperdine-amino-benzimidazole derivatives as inhibitors of respiratory syncytial virus replication | TIBOTEC PHARMACEUTICALS (IE) | 2008-04-08 | — | — | US | disclosed |
| US-7355051-B2 | Piperdine-amino-benzimidazole derivatives as inhibitors of respiratory syncytial virus replication | TIBOTEC PHARMACEUTICALS (IE) | 2008-04-08 | — | — | US | disclosed |
| US-20070093659-A1 | Piperdine-amino-benzimidazole derivatives as inhibitors of respiratory syncytial virus replication | JANSSEN SCIENCES IRELAND UC (IE) | 2007-04-26 | — | — | US | disclosed |
| US-20070093659-A1 | Piperdine-amino-benzimidazole derivatives as inhibitors of respiratory syncytial virus replication | JANSSEN SCIENCES IRELAND UC (IE) | 2007-04-26 | — | — | US | disclosed |
| WO-2005058873-A1 | PIPERIDINE-AMINO-BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093659-A1 | Piperdine-amino-benzimidazole derivatives as inhibitors of respiratory syncytial virus replication | NQO2, NOX1, NOX3 | NPY1R 3876/4885CCR8 2861/4885SSTR5 4287/4885 |
| US-20080146613-A1 | PIPERIDINE-AMINO-BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | NQO2, NOX3, NOX1 | NPY1R 3988/4885CCR8 2744/4885SSTR5 4354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.